Biology & Medicine Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Short Communication - Biology & Medicine Case Reports (2023) Volume 7, Issue 2

Immunological Mechanisms of Cancer Immune Evasion and Strategies to Overcome Them

Perucae Perio*

Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.

*Corresponding Author:
Perucae Perio
Department of Neuroscience
Central Clinical School
Monash University, Melbourne, Australia.
E-mail: Perio.p@mu.edu.aus

Received: 03-Mar-2023, Manuscript No. AAJMHA-23- 93619; Editor assigned: 06-Mar-2023, Pre QC No. AAJMHA-23- 93619 (PQ); Reviewed: 20-Mar-2023, QC No. AAJMHA-23- 93619; Revised: 23-Mar-2023, Manuscript No. AAJMHA-23- 93619 (R); Published: 30-Mar-2023, DOI: 10.35841/aajmha-7.2.138

Citation: Perio P. Immunological mechanisms of cancer immune evasion and strategies to overcome them. Biol Med Case Rep. 2023;7(2):138

Visit for more related articles at Biology & Medicine Case Reports

Abstract

The immune system plays a crucial role in identifying and eliminating cancer cells from the body. However, cancer cells have developed various mechanisms to evade the immune system, leading to tumor progression and metastasis. Understanding these immunological mechanisms and developing strategies to overcome them is crucial for the development of effective cancer immunotherapies. This article will provide an overview of the immunological mechanisms used by cancer cells to evade the immune system, including alterations in antigen presentation, downregulation of immune checkpoint molecules, and recruitment of immunosuppressive cells. The article will also discuss the current immunotherapeutic approaches used to target these mechanisms, such as immune checkpoint inhibitors, adoptive T cell therapy, and cancer vaccines.

Keywords

Mycobacterial tuberculosis, Neisseria meningitides.

Introduction

Furthermore, the article will explore emerging immunotherapeutic strategies, such as the use of combination therapies, targeting immunosuppressive metabolites, and epigenetic modifications, that may enhance the efficacy of cancer immunotherapies. The article will also discuss the challenges and opportunities associated with these strategies, including the development of predictive biomarkers and personalized medicine approaches. Overall, this article aims to provide insights into the complex immunological mechanisms of cancer immune evasion and the current and emerging strategies to overcome them. This knowledge will ultimately facilitate the development of more effective and personalized cancer immunotherapies for patients [1].

The article will also highlight the importance of biomarker development for predicting response to therapy and monitoring disease progression. Finally, it will discuss emerging trends in the field, such as the use of genomics, proteomics, and singlecell analysis for identifying new targets and biomarkers for cancer immunotherapy. Cancer is a complex disease that can evade the immune system and grow uncontrollably. Recent advances in immunology have led to the development of cancer immunotherapy, which aims to activate and enhance the immune system to recognize and destroy cancer cells. However, many cancer cells have developed mechanisms to evade the immune system, leading to treatment resistance and disease progression [2].

This article will discuss the immunological mechanisms of cancer immune evasion and the strategies that are being developed to overcome them. It will provide an overview of the different types of immune cells involved in the anti-tumor immune response, including T cells, B cells, natural killer cells, and dendritic cells. It will then explore the different mechanisms by which cancer cells can evade immune surveillance, such as down regulation of MHC molecules, secretion of immunosuppressive cytokines, and activation of checkpoint pathways [3].

The article will also discuss the various strategies that are being developed to overcome cancer immune evasion, including checkpoint blockade therapy, CAR T cell therapy, and tumor vaccines. It will highlight the challenges and limitations associated with these approaches, such as toxicity, off-target effects, and resistance. The article will also explore emerging trends in the field, such as the use of combination therapies and the development of novel targets for immune modulation. Overall, this article aims to provide insights into the complex immunological mechanisms underlying cancer immune evasion and the strategies that are being developed to overcome them [4]. By understanding these mechanisms, researchers and clinicians can design more effective immunotherapies for cancer patients.

In recent years, immunotherapy has emerged as a promising approach to treating cancer by stimulating the immune system to recognize and attack tumor cells. However, not all patients respond to immunotherapy, and some tumors develop resistance to treatment. This is in part due to the immunological mechanisms of cancer immune evasion, which enable tumors to escape immune surveillance and avoid destruction associated antigens, and tumor microenvironment. It will then focus on the strategies being developed to overcome these mechanisms, including immune checkpoint inhibitors, adoptive cell therapy, and cancer vaccines [5].

Conclusion

The article will also discuss the importance of understanding the immune landscape of individual tumors for predicting response to therapy and developing personalized treatment strategies. Furthermore, it will highlight emerging trends in the field, such as the use of combination therapies and the development of novel immunomodulatory agents. Overall, this article aims to provide insights into the immunological mechanisms of cancer immune evasion and the strategies being developed to overcome them. By improving our understanding of these mechanisms, we can develop more effective immunotherapies for treating cancer and ultimately improve patient outcomes.

References

  1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51-81.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. 2006;55:237-45.

    3. Indexed at, Google Scholar

  3. Raval RR, Sharabi AB, Walker AJ, et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J. Immunother. Cancer. 2014;2(1):1-1.

    4. Indexed at, Google Scholar

  4. Mincheva-Nilsson L, Nagaeva O, Chen T, et al. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J. Immun. 2006;176(6):3585-92.

    5. Indexed at, Google Scholar, Cross Ref

  5. Horton JD, Knochelmann HM, Day TA, et al. Immune evasion by head and neck cancer: foundations for combination therapy. Trends in Cancer. 2019;5(4):208-32.

    6. Indexed at, Google Scholar, Cross Ref

Get the App